NASDAQ:NBTX Nanobiotix Q4 2025 Earnings Results & Report $30.66 -1.59 (-4.93%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$30.70 +0.04 (+0.15%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Nanobiotix reported Q4 2025 earnings on February 15, 2026. The company reported EPS of -$0.23, while revenue was $3.42 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 15, 2026TimeAfter Market Closes Nanobiotix EPS ResultsActual EPS-$0.23Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANanobiotix Revenue ResultsActual Revenue$3.42 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Nanobiotix Q4 2025 Earnings FAQ Did Nanobiotix beat earnings estimates for Q4 2025? Nanobiotix (NASDAQ:NBTX) reported earnings of -$0.23 per share for Q4 2025. The report was announced on Sunday, February 15, 2026. What was Nanobiotix's revenue for Q4 2025? Nanobiotix reported revenue of $3.42 million for Q4 2025. Nanobiotix Earnings HeadlinesVoting Rights and Shares Capital of the CompanyNovember 12 at 4:15 PM | globenewswire.comNanobiotix to Participate in Investor Conferences in NovemberNovember 9, 2026 | finance.yahoo.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 15 at 1:00 AM | Behind the Markets (Ad)Nanobiotix: The Phase 3 May Come Later, And Lenders Get Paid FirstOctober 30, 2026 | seekingalpha.comNanobiotix stock gains on positive melanoma trial dataOctober 26, 2026 | uk.finance.yahoo.comNANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous MelanomaOctober 24, 2026 | globenewswire.comSee More Nanobiotix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nanobiotix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanobiotix and other key companies, straight to your email. Email Address About NanobiotixNanobiotix (NASDAQ:NBTX) is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue. Nanobiotix is studying NBTXR3 in clinical programs for several cancer types, including head and neck cancers. NBTXR3 has received CE marking in Europe for use with radiation therapy in adults with locally advanced soft tissue sarcoma. Nanobiotix is headquartered in France and conducts development activities across international markets.View Nanobiotix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
